Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 12, 2016 07:00 ET | Source: MacroGenics, Inc.

Takeda and MacroGenics Announce the Conclusion of their MGD010 License and Option Agreement

Rockville, MD, Sept. 12, 2016 (GLOBE NEWSWIRE) -- and Osaka, Japan, Sept. 12, 2016 -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and...
August 31, 2016 07:30 ET | Source: MacroGenics, Inc.

MacroGenics to Participate in Two Upcoming Investor Conferences

Rockville, MD, Aug. 31, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
August 04, 2016 07:30 ET | Source: MacroGenics, Inc.

MacroGenics to Participate in Two Upcoming Investor Conferences

Rockville, MD, Aug. 04, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
August 03, 2016 16:02 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and Second Quarter 2016 Financial Results

MGD010 Phase 1 clinical DART® data presented at EULAREntered into collaboration with Janssen to develop MGD015On track for three new IND submissions in 2016-2017 ROCKVILLE, Md., Aug. 03, 2016 ...
July 27, 2016 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of Second Quarter 2016 Financial Results Conference Call

Rockville, MD, July 27, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, August 3, 2016, the Company will release its financial results for the...
June 28, 2016 07:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Closing of Collaboration and License Agreement with Janssen to Develop MGD015

Rockville, MD, June 28, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
June 10, 2016 06:00 ET | Source: MacroGenics, Inc.

MacroGenics Presents Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology (EULAR 2016)

Bispecific molecule based on DART® platform simultaneously targets B-cell antigens, CD32B and CD79B MGD010 was well tolerated at all dose levels with no serious adverse effects ...
May 18, 2016 06:00 ET | Source: MacroGenics, Inc.

MacroGenics Enters Collaboration and License Agreement with Janssen to Develop New DART Molecule for Treatment of Cancer

MacroGenics licenses MGD015 to Janssen$75 Million upfront license fee paid to MacroGenicsMacroGenics may elect to fund a portion of late-stage development costs in exchange for a U.S. and...
May 11, 2016 16:35 ET | Source: MacroGenics, Inc.

MacroGenics to Present MGD010 Clinical Data at EULAR 2016

ROCKVILLE, Maryland, May 11, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative...
May 10, 2016 07:30 ET | Source: MacroGenics, Inc.

First Dosing of Pfizer DART Candidate in Phase 1 Study Triggers Milestone Payment to MacroGenics

ROCKVILLE, Md., May 10, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that its collaboration partner, Pfizer Inc. (NYSE: PFE), has advanced a bispecific antibody...